Omeros: The Prize Is Nigh

Photo by brainmaster/E+ via Getty Images
This summer Omeros (NASDAQ:OMER) has a big PDUFA scheduled for 07/2021. In this article I review the various issues for investors to consider when evaluating Omeros leading into this important event.
I am quite optimistic, albeit watchfully so.
Omeros’ upcoming PDUFA date will be transformative for the company.
Omeros’ 07/17/21 PDUFA date for narsoplimab (OMS721, MASP-2) in treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy…

Click here to view the original article.